Provectus (OTCMKTS:PVCT) Stock Falls After Announcing Oral Presentation of Updated Study Data
Provectus (OTCMKTS:PVCT) dropped 4% after announcing data from its ongoing clinical study of experimental cancer immunotherapy PV-10 in treating neuroendocrine tumors metastatic to the liver refractory to somatostatin analogy and peptide receptor radionuclide therapy at the European Neuroendocrine Tumor Society’s annual conference that took place on March 10-11 2022 in Barcelona, Spain, and virtually.
Market Stats
On Wednesday, PVCT stock went down 3.90% to $0.0665 with 73K shares, compared to its average volume of 214K shares. The stock moved within a range of $0.0655 – 0.0693 after opening trading at $0.0693.
Provectus Biopharmaceuticals Announces Oral Presentation of Updated Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference
The Company’s Board of Directors Vice Chair Dominic Rodriguez said that study data demonstrate promising systemic and local disease and symptoms control, especially in heavily pre-treated individuals. Also, the findings support PV-10 monotherapy’s role as a neuroendocrine cancer patients treatment for those failing standard therapy.
Rodriguez added that PV-10-led combined neuroendocrine cancer therapies represent prospects for enhancing clinical outcomes and quality of life. Frontline approaches include combination of liver-directed PV-10 therapy with systematically administered immune checkpoint inhibitors to support PV-10’s immune activity or utilizing PV-10 to improve cytotoxic treatments’ activity like peptide receptor radionuclide therapy. So in the coming weeks, investors should watch PVCT.
Key Quote
Dominic Rodrigues, Vice Chair of the Company’s Board of Directors, said, “Study data continue to show encouraging local and systemic disease control, as well as symptom control, in a heavily pre-treated population and to support a role for monotherapy PV-10 as a treatment for neuroendocrine cancer patients who fail standard therapy.”
Traders Corner
PVCT stock is trading below the 20-Day and 50-Day Moving averages of $0.0666 and $0.0672 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0630.
